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(N[ 98)Denovo Group
(N[ 65) P (<0.05) Odds Ratio (CI)Primary patency
(Primary Endpoint)41/81 (51%) 20/41 (49%) 0.84 1 (0.5-2.2)Secondary Endpoint 66/98 (67%) 37/65 (57%) 0.17 1.5 (0.8-2.9)Cumulative blockage
(ISRSþ Re-
occlusion)58/98 (59%) 28/65 (43%) 0.04 1.96 (1-3.6)Restenosis 35/98 (47%) 20/65 (35%) 0.09 1.6 (0.7-3.2)Target Lesion
Revascularization57/98 (58%) 16/65 (25%) <0.0001 4.2 (2.1-8.5)TLR (Percutaneous
Intervention)51/98 (52%) 14/65 (22%) <0.0001 3.9 (1.9-8)TLR (Surgical
revascularization)21/98 (21%) 3/65 (5%) 0.003 5.6 (1.6-19)Amputation 18/98 (18%) 15/65 (23%) 0.46 0.7 (0.3-1.6)Primary Endpoint: Primary patency at 12 month of follow-up by either angiogram or Doppler scan
Secondary Endpoint: Amputation, Cumulative blockage ( ISRS þThrombotic re-occlusion), TLR (Percuta-
neous intervention and surgical revascularization)CONCLUSIONS Stent graft treatment using the Gore Viabahn for De
novo and ISRS in femoro-popliteal arterial obstructive disease have
high restenosis and failure rates, of both stent patency and limb
outcomes, which is consistent with existed literature. Failure of stent
grafts, used to treat ISRS associated with higher rates of TLR, occlu-
sion requiring bypass, compared to De novo lesions.
CATEGORIES ENDOVASCULAR: Peripheral Vascular Disease and
Intervention
KEYWORDS Femoropopliteal artery, In-stent restenosis, Prognosis
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ripheral artery interventional (PAI) procedures in patients with
symptomatic peripheral artery disease (PAD) over the last decade,
adherence to guideline-based medical therapy (GMT) post-revascu-
larization has not been well described.
METHODS We analyzed PAIs registered in the Excellence in Peripheral
Artery Disease (XLPAD) registry (NCT01904851) from 13 U.S. centers
between 2005 and 2013 and evaluated adherence to GMT which is
comprised antiplatelet therapy (APT), lipid-lowering therapy (LLT) and
renin-angiotensin pathway inhibitors (RAI) with angiotensin receptor
blockers (ARB) and angiotensin converting enzyme inhibitors (ACEI).
RESULTS Analysis of 1532 PAI in the study periods (n¼55 in 2005-2007;
n¼314 in 2008-2010 and n¼1,163 in 2011-2013) demonstrates an exponen-
tial rise in PAIs, consistentwith national U.S. trends. Nevertheless, this rise
in PAI was not accompanied with an equally robust adherence to GMT.
Excluding, the limited number of patients enrolled from 2005-2007, the
period between 2008 and 2013, demonstrates suboptimal adherence to
GMTacross all therapygroups (Figure 1). APTprescriptions fell from90%to
77%, between 2008-2010 and 2011-2013 (p<0.001), and dual-APT
prescriptions remained consistently low during the periods (53% vs.
48%). Consistent with the overall trend of dropping adherence to GMT
between the periods 2008-2010 and 2011-2013 (55% vs. 42%; p<0.001),
individual prescription of LLT and RAI were also signiﬁcantly lower (83%
vs. 66% for LLT; p<0.001 and 62% vs. 49% for RAI; p<0.001),
respectively. During the same periods, all-cause death and non-fatal
myocardial infarction (MI) rates were 7% and 5%, and need for repeat
endovascular revascularization (RR) rates remain high at 28% and 19%
for the periods 2008-2010 and 2011-2013, respectively.
CONCLUSIONS Given the high death, MI and RR rates in patients un-
dergoing PAI, and suboptimal adherence to GMT, there is an urgent need
for national performance standards to monitor GMT in patients with PAD.CATEGORIES ENDOVASCULAR: Peripheral Vascular Disease and In-
tervention
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BACKGROUND A number of small studies have suggested that out-
comes following endovascular therapy (ENDO) are comparable to
those following surgical revascularization (SURG) for patients pre-
senting with acute limb ischemia (ALI). We sought to compare mor-
tality, limb amputation and recurrent ischemia across both strategies.
METHODS MEDLINE, EMBASE and CENTRAL electronic databases
were comprehensively searched from January 1990 through May 2015
to identify studies of ENDO versus SURG for ALI. Two independent
reviewers selected studies and extracted the data. Random-effects
meta-analysis was used to pool results across studies. Heterogeneity of
treatment effect among trials was assessed using the I2 statistics. The
primary endpoints were mortality and limb amputation at 1, 6 and 12
months. Secondary endpoint was recurrent ischemia at one year.
